DermNet provides Google Translate, a free machine translation service. Note that this may not provide an exact translation in all languages


Haemolytic uraemic syndrome

Author: Dr Rebecca Irwin, Junior Registrar, Basic Medicine Trainee, Waikato Hospital, Hamilton, New Zealand. Copy edited by Gus Mitchell. July 2021


What is haemolytic uraemic syndrome?

Haemolytic uraemic syndrome (HUS), a form of thrombotic microangiopathy, is defined by the clinical triad of thrombocytopenia, anaemia, and acute kidney damage.

Who gets haemolytic uraemic syndrome?

Haemolytic uraemic syndrome is one of the leading causes of acute kidney damage in children and is becoming increasingly common in adults.

  • Typical HUS:
    • Mainly affects children (under five years of age) and the elderly
    • Estimated overall annual incidence 2 cases/100000 and up to 6/100000 in young children
    • Most common in summer months and rural areas
    • Can be sporadic or in outbreaks large or small
    • Increased risk of HUS developing if antibiotics and antimotility agents are used during the diarrhoeal phase.
  • Atypical HUS (aHUS):
    • Rare
    • Affects children under 2 years of age and adults
    • Annual incidence 0.5–2 per million
    • Can be isolated or familial.

What causes haemolytic uraemic syndrome?

The pathophysiology of HUS involves vascular endothelial cell damage which increases the risk of thrombosis and organ damage, particularly of the kidneys. Disorders of the complement system may predispose to the development of HUS in response to specific triggers, with the resultant dysregulation of the complement cascade.

Haemolytic uraemic syndrome can be classified as:

  • Typical infection-related HUS (90%) is usually due to Shiga toxin-producing bacteria such as enterohaemorrhagic E. coli (STEC), Shigella dysenteriae, or non-Shiga toxin-associated diarrhoeal infections. Less commonly other infections can be implicated such as pneumococcal pneumonia and HIV/AIDS.
  • Atypical HUS (10%) results from many different diseases producing the HUS clinical pattern — 

What are the clinical features of haemolytic uraemic syndrome?

Haemolytic uraemic syndrome presents with:

  • Pallor
  • Acute kidney failure — oedema, nausea and vomiting, reduced urine output, high blood pressure
  • Extrarenal manifestations such as shortness of breath and neurological symptoms and signs (irritability, confusion, seizures, decreased level of consciousness).

Skin signs are nonspecific and may include jaundice, bleeding and bruising, petechiae, livedo reticularis, and purpura.

Shiga toxin-related HUS

  • Onset of abdominal pain and bloody diarrhoea, which can be severe, 4–7 days after ingestion of contaminated food or water
  • Abrupt onset of HUS symptoms and signs 2–10 days later

Atypical HUS

  • Usually triggered by a respiratory or gastrointestinal febrile illness
  • Onset of HUS manifestations usually less abrupt than in typical HUS
  • Recurrent episodes not associated with one specific trigger

What are the complications of haemolytic uraemic syndrome?

Diarrhoea-associated haemolytic uraemic syndrome may be complicated by:

  • Rectal prolapse
  • Colonic gangrene
  • Bowel perforation.

Neurological complications of HUS include stroke and coma.

How is haemolytic uraemic syndrome diagnosed?

Haemolytic uraemic syndrome is diagnosed on the following findings:

  • Haematology
    • Anaemia — haemoglobin < 80g/L
    • Fragmented red cells (schistocytes, helmet cells) and reticulocytes
    • Thrombocytopenia — platelet count <140000/mm3
    • Haemolysis — negative Coombs test, high lactate dehydrogenase, high bilirubin, low haptoglobin
  • Kidney
    • Peripheral blood — elevated creatinine and urea
    • Urinalysis — haematuria, proteinuria, red cell casts.

The cause and complications of HUS should be investigated.

  • Stool sample
  • Autoimmune panel
  • Complement studies
  • Other specific tests as clinically indicated including for complications

What is the differential diagnosis for haemolytic uraemic syndrome?

What is the treatment for haemolytic uraemic syndrome?

General measures

  • Management of fluids, electrolytes, pH, and nutrition
  • Blood pressure control
  • Transfusion — if haemoglobulin <60g/L or platelets <10000/mm3

Specific measures

  • Typical HUS — supportive care including dialysis if required
  • Atypical HUS — depends on the cause and severity but may include:
    • Plasma exchange
    • Eculizumab
    • Specific treatment if required for the underlying cause.

What is the outcome for haemolytic uraemic syndrome?

Haemolytic uraemic syndrome can cause acute and/or end-stage renal failure. Most patients with Shiga toxin-related HUS recover fully. Poor prognostic signs include neurological symptoms, low neutrophil count, low platelet count, and prolonged anuria.

The prognosis for atypical HUS depends on the associated trigger. Eculizumab, if available, has improved outcomes.



  • Agarwal HS, Latifi SQ. Streptococcus pneumoniae-associated hemolytic uremic syndrome in the era of pneumococcal vaccine. Pathogens. 2021;10(6):727. doi:10.3390/pathogens10060727. Journal
  • Canpolat N. Hemolytic uremic syndrome. Turk Pediatri Ars. 2015;50(2):73–82. doi:10.5152/tpa.2015.2297. Journal
  • Gomes SM, Teixeira RP, Rocha G, et al. Neonatal atypical hemolytic uremic syndrome in the eculizumab era. AJP Rep. 2021;11(2):e95–8. doi:10.1055/s-0041-1731057. Journal
  • Jokiranta TS. HUS and atypical HUS. Blood. 2017;129(21):2847–56. doi:10.1182/blood-2016-11-709865. Journal
  • Karpman D, Loos S, Tati R, Arvidsson I. Haemolytic uraemic syndrome. J Intern Med. 2017;281(2):123–48. doi:10.1111/joim.12546. Journal
  • McFarlane PA, Bitzan M, Broome C, et al. Making the correct diagnosis in thrombotic microangiopathy: a narrative review. Can J Kidney Health Dis. 2021;8:20543581211008707. doi:10.1177/20543581211008707. Journal
  • Medical Masterclass contributors, Firth J. Nephrology: thrombotic microangiopathy (haemolytic-uraemic syndrome). Clin Med (Lond). 2019;19(1):72–4. doi:10.7861/clinmedicine.19-1-72. Journal
  • Sheerin NS, Glover E. Haemolytic uremic syndrome: diagnosis and management. F1000Res. 2019;8:F1000 Faculty Rev-1690. doi:10.12688/f1000research.19957.1. Journal
  • Walsh PR, Johnson S. Treatment and management of children with haemolytic uraemic syndrome. Arch Dis Child. 2018;103(3):285–91. doi:10.1136/archdischild-2016-311377. PubMed
  • Walsh PR, Johnson S. Eculizumab in the treatment of Shiga toxin haemolytic uraemic syndrome. Pediatr Nephrol. 2019;34(9):1485–92. doi:10.1007/s00467-018-4025-0. Journal

On DermNet NZ

Other websites

Books about skin diseases



Related information

Sign up to the newsletter